NCT03693508View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 13, 2018

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions
HIV InfectionsSevere Immunosuppression
Interventions
DRUG

Genvoya®

Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.

Trial Locations (6)

28034

H. Ramón y Cajal, Madrid

28040

H. Clínico San Carlos, Madrid

28041

H. Doce de Octubre, Madrid

41013

Hospital virgen del Rocío, Seville

Unknown

Hospital Costa del Sol, Marbella

Hospital Infanta Leonor, Madrid

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT03693508 - A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression | Biotech Hunter | Biotech Hunter